The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_000546.5(TP53):c.1163A>C (p.Glu388Ala)

CA000047

141425 (ClinVar)

Gene: TP53 (HGNC:7157)
Condition: Li-Fraumeni syndrome (MONDO:0018875)
Inheritance Mode: Autosomal dominant inheritance
UUID: 4ef47921-0407-4ece-a6d2-91823363a565
Approved on: 2026-08-06
Published on: 2026-09-22

HGVS expressions

NM_000546.5:c.1163A>C
NM_000546.5(TP53):c.1163A>C (p.Glu388Ala)
NC_000017.11:g.7669628T>G
CM000679.2:g.7669628T>G
NC_000017.10:g.7572946T>G
CM000679.1:g.7572946T>G
NC_000017.9:g.7513671T>G
NG_017013.2:g.22923A>C
ENST00000503591.2:c.1163A>C
ENST00000508793.6:c.1163A>C
ENST00000509690.6:c.767A>C
ENST00000514944.6:c.884A>C
ENST00000604348.6:c.1142A>C
ENST00000269305.9:c.1163A>C
ENST00000269305.8:c.1163A>C
ENST00000359597.8:c.994-3384A>C
ENST00000413465.6:c.782+4553A>C
ENST00000420246.6:c.*270A>C
ENST00000445888.6:c.1163A>C
ENST00000455263.6:c.*182A>C
ENST00000504290.5:c.*182A>C
ENST00000504937.5:c.767A>C
ENST00000510385.5:c.*270A>C
ENST00000576024.1:c.116A>C
ENST00000610292.4:c.1046A>C
ENST00000610538.4:c.*182A>C
ENST00000610623.4:c.*182A>C
ENST00000615910.4:c.1130A>C
ENST00000617185.4:c.*270A>C
ENST00000618944.4:c.*270A>C
ENST00000619186.4:c.686A>C
ENST00000619485.4:c.1046A>C
ENST00000620739.4:c.1046A>C
ENST00000622645.4:c.*270A>C
ENST00000635293.1:c.983+981A>C
NM_001126112.2:c.1163A>C
NM_001126113.2:c.*182A>C
NM_001126114.2:c.*270A>C
NM_001126115.1:c.767A>C
NM_001126116.1:c.*270A>C
NM_001126117.1:c.*182A>C
NM_001126118.1:c.1046A>C
NM_001276695.1:c.*182A>C
NM_001276696.1:c.*270A>C
NM_001276697.1:c.686A>C
NM_001276698.1:c.*270A>C
NM_001276699.1:c.*182A>C
NM_001276760.1:c.1046A>C
NM_001276761.1:c.1046A>C
NM_001276695.2:c.*182A>C
NM_001276696.2:c.*270A>C
NM_001276697.2:c.686A>C
NM_001276698.2:c.*270A>C
NM_001276699.2:c.*182A>C
NM_001276760.2:c.1046A>C
NM_001276761.2:c.1046A>C
NM_000546.6:c.1163A>C
NM_001126112.3:c.1163A>C
NM_001126113.3:c.*182A>C
NM_001126114.3:c.*270A>C
NM_001126115.2:c.767A>C
NM_001126116.2:c.*270A>C
NM_001126117.2:c.*182A>C
NM_001126118.2:c.1046A>C
NM_001276695.3:c.*182A>C
NM_001276696.3:c.*270A>C
NM_001276697.3:c.686A>C
NM_001276698.3:c.*270A>C
NM_001276699.3:c.*182A>C
NM_001276760.3:c.1046A>C
NM_001276761.3:c.1046A>C
More

Benign

Met criteria codes 4
BP4 PM2_Supporting BS2 BS3
Not Met criteria codes 19
BP3 BP2 BP1 BP7 PS4 PS2 PS3 PS1 PP1 PP3 PP2 PM6 PM4 PM1 PM5 PVS1 BA1 BS4 BS1

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for TP53 Version 2.4

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
TP53 VCEP
The NM_000546.6: c.1163A>C variant in TP53 is a missense variant predicted to cause substitution of glutamic acid by alanine at amino acid 388 (p.Glu388Ala). This variant has been observed in 4-7 heterozygous unrelated females from the same data source with no personal history of cancer prior to age 60 years and no personal history of sarcoma at any age (BS2_Moderate; Internal lab contributors). This variant has an allele frequency of 0.000008054 (13/1614128 alleles) across gnomAD v4.1.1 which is lower than the Clingen TP53 VCEP threshold (<0.00003) for PM2_Supporting and has a subpopulation allele frequency of <0.00004 in all non-bottleneck populations with 2 or more alleles present (PM2_Supporting). In vitro assays performed in yeast and/or human cell lines showed functional transactivation and retained growth suppression activity by the majority of available assays indicating that this variant does not impact protein function (BS3; PMIDs: 12826609, 30224644). Computational predictor scores (BayesDel = -0.0336; Align GVGD Class 0) are below the recommended thresholds (BayesDel ≤ -0.008 and an Align GVGD Class ≤ 55), evidence that does not predict a damaging effect on TP53 via protein change. SpliceAI predicts that the variant has no impact on splicing. (BP4_Moderate). This variant does not reside within a region of TP53 that is defined as a mutational hotspot by the ClinGen TP53 VCEP (PM1 not met). In summary, this variant meets the criteria to be classified as Benign for Li Fraumeni syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: BS2_Moderate, PM2_Supporting, BS3, BP4_Moderate. (Bayesian Points: -7; VCEP specifications version 2.4).
Met criteria codes
BP4
BP4_MODERATE Computational predictor scores (BayesDel = -0.0336; Align GVGD Class 0) are below the recommended thresholds (BayesDel ≤ -0.008 and an Align GVGD Class ≤ 55), evidence that does not predict a damaging effect on TP53 via protein change. SpliceAI predicts that the variant has no impact on splicing. (BP4_Moderate).
PM2_Supporting
This variant has an allele frequency of 0.000008054 (13/1614128 alleles) across gnomAD v4.1.1 which is lower than the Clingen TP53 VCEP threshold (<0.00003) for PM2_Supporting and has a subpopulation allele frequency of <0.00004 in all non-bottleneck populations with 2 or more alleles present (PM2_Supporting).
BS2
BS2_MODERATE This variant has been observed in 4-7 heterozygous unrelated females from the same data source with no personal history of cancer prior to age 60 years and no personal history of sarcoma at any age (BS2_Moderate; Internal lab contributors).
BS3
In vitro assays performed in yeast and/or human cell lines showed functional transactivation and retained growth suppression activity by the majority of available assays indicating that this variant does not impact protein function (BS3; PMIDs: 12826609, 30224644).
Not Met criteria codes
BP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP7
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS1
The current variant is the only variant found in this codon in ClinVar.
PP1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM6
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM1
This variant does not reside within a region of TP53 that is defined as a mutational hotspot by the ClinGen TP53 VCEP (PM1 not met).
PM5
The current variant is the only variant found in this codon in ClinVar.
PVS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS4
Li et al. 2016 (PMID: 26534844): Figure 1, family 71, 2 individuals with a personal history of BC (no LFS criteria or Chompret ), in 4 unaffected individuals, and absent in 1 individual with a personal history of BC
BS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
ClinGen Terms of Use.
¤ Powered by BCM's Genboree.